Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;58(3):941-948.
doi: 10.1002/ppul.26282. Epub 2022 Dec 29.

High flow nasal cannula therapy in the pediatric home setting

Shay Ehrlich  1 , Inbal Golan Tripto  2   3 , Moran Lavie  4   5 , Michal Cahal  4   5 , Tommy Shonfeld  1   5 , Dario Prais  1   5 , Hagit Levine  1   5 , Meir Mei-Zahav  1   5 , Ophir Bar-On  1   5 , Yulia Gendler  6 , Jonatan Zalcman  1 , Eahab Sarsur  1 , Micha Aviram  2   3 , Aviv Goldbart  2   3 , Patrick Stafler  1   5
Affiliations

High flow nasal cannula therapy in the pediatric home setting

Shay Ehrlich et al. Pediatr Pulmonol. 2023 Mar.

Abstract

Background: High-flow nasal cannula (HFNC) therapy may be better tolerated than traditional noninvasive ventilation (NIV) and is rapidly gaining acceptance in pediatric acute care. In Israel, HFNC is approved for domestic use. We aim to describe its indications, efficacy, parental satisfaction, and safety.

Methods: Retrospective study of children treated with home HFNC therapy in three pediatric centers. Data included demographic parameters, indication of use, weight and days of hospitalization before and after initiation. Safety, tolerability, and parental satisfaction were assessed via standardized telephone questionnaire.

Results: Median (interquartile range [IQR]) age of initiating home HFNC in 75 children was 8.3 (2.2, 29.6) months. Indications were obstructive sleep apnea (33; 44%), airway malacia (19; 25%), chronic lung disease (15; 20%), neuromuscular disease (4; 5%), and postextubation support (4; 5%). Weight standard deviation score rose from -2.3 pre-HFNC to -1.7 at 6.7 months post-HFNC initiation, p < 0.001. Hospital admission days during the 2 months pre- versus post-HFNC initiation were 22 (5.5, 60) and 5 (0, 14.7) respectively, p < 0.008. Median (IQR) parental satisfaction score was 5/5 (4, 5). Fifty of 60 (83%) respondents would recommend home HFNC to other families in a similar situation. There were no serious adverse events.

Conclusion: In our population, domestic HFNC appeared safe and well tolerated for a variety of indications. Its introduction was associated with improved weight gain, fewer hospitalization days and high parental satisfaction. Further work is required to characterize groups of children most likely to benefit from HFNC, as opposed to traditional modes of NIV.

Keywords: chronic lung disease; high flow nasal cannula; home therapy; noninvasive ventilation; pediatric.

PubMed Disclaimer

References

REFERENCES

    1. Nedel WL, Deutschendorf C, and Moraes Rodrigues Filho E. High-flow nasal cannula in critically ill subjects with or at risk for respiratory failure: a systematic review and meta-analysis. Respir Care. 2017;62:123-132.
    1. Dysart K, Miller TL, Wolfson MR, and Shaffer TH. Research in high flow therapy: mechanisms of action. Respir Med. 2009;103:1400-1405.
    1. Milési C, Boubal M, Jacquot A, et al. High-flow nasal cannula: recommendations for daily practice in pediatrics. Ann Intensive Care. 2014;4:29.
    1. Mauri T, Turrini C, Eronia N, et al. Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure. Am J Respir Crit Care Med. 2017;195:1207-1215.
    1. Franklin D, Babl FE, Schlapbach LJ, et al. A randomized trial of high-flow oxygen therapy in infants with bronchiolitis. N Engl J Med. 2018;378:1121-1131.

LinkOut - more resources